91 related articles for article (PubMed ID: 12021535)
1. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients.
Demirkan F; Akarsu M; Sifil A; Tutucu KN
Nephron; 2002 May; 91(1):162-3. PubMed ID: 12021535
[TBL] [Abstract][Full Text] [Related]
2. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
Kaiser B; Glusa E; Hoppensteadt DA; Breddin HK; Amiral J; Fareed J
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):517-23. PubMed ID: 9819002
[TBL] [Abstract][Full Text] [Related]
3. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients.
Sifil A; Mermut C; Yenicerioglu Y; Cavdar C; Gumustekin M; Celik A; Yuksel F; Camsari T
Adv Perit Dial; 2003; 19():28-30. PubMed ID: 14763030
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
Mousa SA; Johansen K
Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
[TBL] [Abstract][Full Text] [Related]
9. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
Mousa SA; Bozarth J; Barrett JS
J Clin Pharmacol; 2003 Jul; 43(7):727-34. PubMed ID: 12856386
[TBL] [Abstract][Full Text] [Related]
11. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
Brown JR; Kuter DJ
Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
[TBL] [Abstract][Full Text] [Related]
12. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins.
Bendz B; Andersen TO; Sandset PM
Blood Coagul Fibrinolysis; 2000 Jun; 11(4):343-8. PubMed ID: 10847421
[TBL] [Abstract][Full Text] [Related]
14. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Hoppensteadt DA; Walenga JM; Fasanella A; Jeske W; Fareed J
Thromb Res; 1995 Jan; 77(2):175-85. PubMed ID: 7740509
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers.
Hoffmann U; Harenberg J; Bauer K; Huhle G; Tolle AR; Feuring M; Christ M
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):289-96. PubMed ID: 12032393
[TBL] [Abstract][Full Text] [Related]
16. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.
Abildgaard U
Haemostasis; 1993 Mar; 23 Suppl 1():103-6. PubMed ID: 8388347
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
19. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
20. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients.
Cianciolo G; La Manna G; Donati G; Dormi A; Cappuccilli ML; Cuna V; Legnani C; Palareti G; Colì L; Stefoni S
Nephrol Dial Transplant; 2011 Feb; 26(2):646-52. PubMed ID: 20659908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
